Sareum Holdings PLC

Sareum Holdings PLC

Health CarePharmaceuticals & Biotechnology
  • Price (GBX)6.65
  • Today's Change-0.10 / -1.48%
  • Shares traded9.89m
  • 1 Year change+373.31%
  • Beta-0.2858
Data delayed at least 20 minutes, as of Oct 21 2021 17:08 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Sareum Holdings plc is engaged in the discovery and development of new therapeutic drugs by a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's drug programs include Checkpoint Kinase 1 (CHK1), Aurora+FLT3 Kinase and Tyrosine Kinase 2- autoimmune diseases (TYK2), Aurora+FLT3 kinase and TYK2 kinase-cancer. Its Chk1 program is the advanced program and shows potency in disease models of lung and colon cancers in combination with chemotherapy; acute myeloid leukemia (AML) and B-cell lymphoma, and head and neck cancers in combination with radiotherapy. TYK2 kinase program focuses on developing a series of TYK2 inhibitors that can be dosed orally against various autoimmune and inflammatory disorders, including psoriasis and rheumatoid arthritis. Its Aurora+FLT3 Kinase program focuses on AML and other blood cancers. Its TYK2 kinase prevents T-cell acute lymphoblastic leukemia (T-ALL) cells from proliferating by causing programmed cell death.

  • Revenue in GBP (TTM)47.20k
  • Net income in GBP-926.91k
  • Incorporated2004
  • Employees6.00
  • Location
    Sareum Holdings PLCUnit 2ALangford Arch, London Road, PampisfordCAMBRIDGE CB22 3FXUnited KingdomGBR
  • Phone+44 122 349 7700
  • Fax+44 122 349 7701
  • Websitehttp://www.sareum.co.uk/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
4d Pharma PLC490.00k-67.69m122.60m115.00--3.09--250.21-0.4438-0.44380.00340.220.0112--0.1954,260.87-154.55-32.46-182.79-35.41-----13,813.67-13,963.364.18-54.630.0248--153.08---7.88---27.01--
Scancell Holdings Plc0.00-6.85m175.27m22.00--6.42-----0.0134-0.01340.000.03350.00----0.00-31.68-42.18-38.68-45.64-----------4.330.1248------2.16------
Arix Bioscience PLC468.00k38.88m179.56m330.005.610.649--383.680.24760.24760.00352.140.0018--0.29981,418.1814.50--14.61------8,307.05------0.0005---5.73--281.25------
e-Therapeutics plc317.00k-3.68m180.61m18.00--10.64--569.74-0.0097-0.00970.00090.0330.0332--6.8217,611.11-38.58-44.60-40.02-48.16100.00100.00-1,162.15-3,490.09----0.0017---30.48---56.97---13.19--
Faron Pharmaceuticals Oy0.00-16.99m180.87m30.00--72.33-----0.3521-0.35210.000.0470.00----0.00-153.87-134.84-248.86-258.18-------8,392.69---93.580.5557-------27.78--5.82--
Circassia Group PLC27.10m-19.40m188.82m247.00--2.90--6.97-0.0468-0.03960.06580.15590.2561.871.74109,716.60-18.33-11.82-24.20-13.7967.9076.33-71.59-106.471.40--0.0254---30.9217.22-59.52--10.76--
Bioventix PLC10.93m6.73m190.14m16.0028.5316.0927.6917.401.
Eco Animal Health Group Plc105.61m8.16m193.01m207.0023.852.3110.501.830.11950.11951.531.230.97512.753.41510,178.8015.3710.5520.6613.1450.7748.5315.7714.623.0424.160.015547.1946.4617.51109.456.21-30.72-29.40
Animalcare Group Plc75.10m96.00k223.54m211.002,384.622.7424.362.980.00160.00161.251.360.61142.726.80355,900.500.0782--0.0909--53.23--0.1278--1.026.910.159---0.8858--117.49------
Sareum Holdings Plc47.20k-926.91k227.18m6.00--162.18--4,813.24-0.0003-0.00030.000010.00040.0316--0.70987,866.67-62.02-48.02-71.74-51.95-----1,963.79-9,651.86---24.860.00------32.12------
Allergy Therapeutics plc84.33m2.89m227.84m601.00113.424.7732.462.700.00310.00310.12750.07450.96762.1111.80140,317.803.311.014.191.3373.7974.383.420.92132.5810.780.18710.007.8311.69-59.11--15.77--
Redx Pharma PLC6.61m-17.95m236.74m52.00--11.05--35.79-0.0802-0.08020.03060.07780.2407--3.63---65.30-46.97-84.52-90.7368.23---271.33-92.26---10.180.4286--81.57---113.36---30.43--
Creo Medical Group PLC22.33m-21.16m298.49m245.00--5.09--13.37-0.1346-0.13460.14190.32440.27823.125.08102,891.70-26.37---31.21--45.54---94.79--2.17-53.680.1703--69,899.11---27.68------
Avacta Group Plc4.15m-22.09m319.68m123.00--5.98--77.09-0.0937-0.09370.01750.21060.06128.771.0433,715.45-32.63---34.79--59.49---532.77--8.74-72.100.0343--------------
Synairgen plc0.00-13.92m336.24m18.00--3.92-----0.0986-0.09860.000.42590.00----0.00-30.05-30.56-31.80-33.63-------431.9325.86--0.0015-------258.20--50.02--
Data as of Oct 21 2021. Currency figures normalised to Sareum Holdings PLC's reporting currency: UK Pound GBX

Institutional shareholders

24.34%Per cent of shares held by top holders
HolderShares% Held
Hargreaves Lansdown Stockbrokers Ltd.as of 02 Jul 2021363.00m10.79%
Hargreaves Lansdown Asset Management Ltd.as of 02 Jul 2021196.66m5.84%
HSBC Global Asset Management (UK) Ltd.as of 02 Jul 2021138.17m4.11%
Jarvis Investment Management Ltd.as of 02 Jul 202137.93m1.13%
HSBC Bank Plc (Market-Maker)as of 02 Jul 202125.39m0.75%
IG Markets Ltd.as of 02 Jul 202122.61m0.67%
The Share Centre Ltd.as of 02 Jul 202112.86m0.38%
KW Investment Management Ltd.as of 02 Jul 20219.87m0.29%
Tilney Investment Management Services Ltd.as of 02 Jul 20216.57m0.20%
Walker Crips Investment Management Ltd.as of 02 Jul 20216.26m0.19%
More ▼
Data from 30 Sep 2020 - 01 Oct 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.